Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has shared an announcement.
Shanghai Henlius Biotech, Inc. announced that China’s National Medical Products Administration has approved its application to conduct a clinical trial of HLX43, an anti-PD-L1 antibody-drug conjugate, in combination with HLX07, an anti-EGFR humanised monoclonal antibody, and Hansizhuang (serplulimab) for the treatment of advanced solid tumors in mainland China. The new approval expands Henlius’s growing clinical program around HLX43, which is already in or cleared for multiple Phase 1 and Phase 2 trials across several solid tumor indications and geographies, and strengthens the company’s position in the competitive oncology biologics space by advancing a multi-drug combination strategy that could enhance treatment options for patients with hard-to-treat cancers.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative biologic drugs and biosimilars, particularly monoclonal antibodies and antibody-drug conjugates targeting oncology indications, with a strong emphasis on advanced and metastatic solid tumors in both domestic and international markets.
Average Trading Volume: 911,104
Technical Sentiment Signal: Buy
Current Market Cap: HK$30.73B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.